Caredx Stock Earnings Reports

Key investor takeaways from CareDx Q1 2026 earnings call: 1) Portfolio actions — CareDx announced the divestiture of its Lab Products business to Eurobio Scientific (announced April 15) for $170M in upfront consideration (expected to net ~ $160M after transaction costs) with close expected by end of Q3; this simplifies the company to focus on precision testing services, digital/patient solutions and supports balance sheet flexibility. 2) Strategic acquisition — CareDx announced an agreement to acquire Navaris, a tumor‑naive TTMV (tumor tissue‑modified viral DNA) platform focused on HPV‑driven cancers (head & neck, anal). Navaris has ADLT status with ~$1,800 Medicare reimbursement per test, ~130k commercial tests performed, ~2k ordering physicians, ~100 employees, ~100M covered lives, estimated 2025 revenue ~$34M and projected 30%–40% growth over the next three years. Management views Navaris as a targeted, high‑fit extension of CareDx’s repeat‑testing, specialty workflow model rather than a broad MRD push. 3) Clinical and product pipeline — Progress across transplant and oncology: AlloSure liver development (MAPLE), HistoMap kidney moving toward launch, Alaheme (cell therapy) ACROBAT data progressing, Vantics AI‑enabled insights platform launched, and ongoing registry/interventional studies (ALAMO, SHORE, MERIT) to drive evidence and adoption. 4) Q1 financials — Total revenue $118M (up 39% YoY); testing volume 54,900 (+17% YoY); testing services revenue +48% to $91M; patient & digital solutions +33% to $16M; non‑GAAP gross margin 73%; adjusted EBITDA $19M (300%+ YoY increase); GAAP net income $3M; cash $198M, no debt. 5) Raised 2026 guidance — Revenue guide $447M–$465M (midpoint $456M, +20% YoY), adjusted EBITDA $43M–$57M (midpoint $50M, +58% YoY), testing volume guide 224k–229k tests. Guidance currently assumes the business as‑is (includes Lab Products), with the pro forma impacts of the products carve‑out disclosed and expected net proceeds to strengthen flexibility. 6) Commercial execution & operations — Management is prioritizing workflow integrations (Epic/Aura) and aims for ~50% of testing volume from Epic‑integrated sites by year end; 9 centers live and 16 integrations in progress. 7) Key risks/considerations — reimbursement dynamics (ADLT reporting and potential rate resets), integration risk for Navaris, timing of the MolDX LCD for transplant (management expects mid‑2026), and execution of automation/cost improvements for Navaris labs to drive margin expansion. Overall, investors should view the quarter as operationally strong with accelerated top‑line growth, margin improvement, a clearer strategic focus via the lab products divestiture, and inorganic expansion into a specialty oncology MRD niche via Navaris while maintaining raised full‑year guidance.